Featured Publications

Lancet Dec 2026

Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.

Deborah B Horn, Donna H Ryan, Sanja Giljanovic Kis, et al.

407 mentions

X 180
News 69
YouTube 36
Facebook 36
+6 more

View analytics →

J Clin Oncol Oct 2026

Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement.

Vivek Subbiah, Razelle Kurzrock

21 mentions

LinkedIn 8
X 7
News 4
Bluesky 1
+1 more

View analytics →

Nat Commun Aug 2026

Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial.

Jiayu Wang, Quchang Ouyang, Weimin Xie, et al.

10 mentions

News 8
YouTube 1
Blogs 1

View analytics →

Trends Pharmacol Sci Aug 2026

Orforglipron (Foundayo) for adults with obesity.

Qingtong Zhou, Guanyi Li, Ming-Wei Wang

133 mentions

News 39
Facebook 30
Instagram 30
LinkedIn 28
+3 more

View analytics →

BMJ Jul 2026

Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.

Kailei Nong, Qingyang Shi, Xinran Xie, et al.

235 mentions

Instagram 59
X 45
LinkedIn 39
News 37
+5 more

View analytics →

Nat Med Jul 2026

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.

Louis J Aronne, Deborah B Horn, Carel W le Roux, et al.

192 mentions

News 52
Instagram 41
Facebook 32
LinkedIn 26
+5 more

View analytics →

Lancet Mar 2026

Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.

Julio Rosenstock, Daisuke Yabe, David Cox, et al.

181 mentions

News 58
Instagram 34
Facebook 26
X 22
+4 more

View analytics →

JAMA Feb 2026

Gastric Cancer: A Review.

Anuj Kishor Patel, Nilay S Sethi, Haeseong Park

147 mentions

X 85
News 28
Instagram 13
Facebook 12
+5 more

View analytics →

Australas J Dermatol Feb 2026

Is the Future Oral? Towards Sustainable and Patient-Centered Biologic Treatment in Dermatology.

Conor Larney, Peter Foley, Benjamin S Daniel

27 mentions

News 27

View analytics →

Nat Med Dec 2025

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Gerhardt Attard, Neeraj Agarwal, Julie N Graff, et al.

136 mentions

News 52
Facebook 34
LinkedIn 28
Instagram 8
+4 more

View analytics →

N Engl J Med Nov 2025

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.

Sean Wharton, Louis J Aronne, Adam Stefanski, et al.

720 mentions

X 254
Facebook 112
News 89
LinkedIn 84
+5 more

View analytics →

N Engl J Med Sep 2025

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.

Julio Rosenstock, Stanley Hsia, Luis Nevarez Ruiz, et al.

301 mentions

X 107
Facebook 52
News 50
Instagram 36
+5 more

View analytics →

Cancer Cell Aug 2025

Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression.

Lisa Schweizer, Hilary A Kenny, Rahul Krishnan, et al.

185 mentions

X 75
News 51
Facebook 20
Instagram 14
+4 more

View analytics →

JAMA Apr 2025

Prostate Cancer: A Review.

Ruben Raychaudhuri, Daniel W Lin, R Bruce Montgomery

108 mentions

X 43
News 33
Facebook 11
Reddit 7
+4 more

View analytics →

N Engl J Med Dec 2023

GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

Fariba Pourkarim, Taher Entezari-Maleki

438 mentions

X 325
News 33
Facebook 30
Instagram 26
+5 more

View analytics →

N Engl J Med Dec 2023

GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

William Preston

438 mentions

X 325
News 33
Facebook 30
Instagram 26
+5 more

View analytics →

The New England journal of medicine Sep 2023

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

Sean Wharton, Thomas Blevins, Lisa Connery, et al.

788 mentions

X 502
News 85
Facebook 79
Instagram 40
+6 more

View analytics →

Nature Jul 2023

Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective.

Saima Sidik

201 mentions

X 100
Facebook 44
News 26
Reddit 21
+2 more

View analytics →

Featured

Articles with social media activity

Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.

Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement.

Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial.

Orforglipron (Foundayo) for adults with obesity.

Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.

Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.

Gastric Cancer: A Review.

Is the Future Oral? Towards Sustainable and Patient-Centered Biologic Treatment in Dermatology.

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.

Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression.

Prostate Cancer: A Review.

GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective.

More articles